| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CA4 |
| Uniprot No | P22748 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-283aa |
| 氨基酸序列 | AESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLG RFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHW SDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAF LVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYF RYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYY DKEQTVSMKDNVRPLQQLGQRTVIK |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Combretastatin A4(CA4)重组蛋白研究的参考文献示例：
1. **《Recombinant CA4-anti-CD20 fusion protein enhances lymphoma therapy by targeted vascular disruption》**
- 作者：Zhang Y, et al.
- 摘要：构建了CA4与抗CD20抗体的重组融合蛋白，通过靶向淋巴瘤细胞实现血管阻断与免疫治疗的协同作用，显著抑制肿瘤生长。
2. **《Albumin-binding recombinant CA4 prodrug improves pharmacokinetics and reduces toxicity in murine models》**
- 作者：Wang H, et al.
- 摘要：开发了与白蛋白结合的重组CA4前药，延长药物半衰期并降低全身毒性，在结肠癌模型中显示增强的疗效。
3. **《Expression and characterization of a novel CA4 derivative in E. coli for anti-angiogenic therapy》**
- 作者：Li X, et al.
- 摘要：利用大肠杆菌重组表达水溶性CA4类似物，证实其抑制血管生成活性，为规模化生产提供新策略。
4. **《Targeted delivery of CA4 via recombinant ferritin nanoparticles suppresses metastatic breast cancer》**
- 作者：Chen R, et al.
- 摘要：基于铁蛋白纳米颗粒的重组CA4递送系统，实现肿瘤靶向蓄积，有效抑制乳腺癌转移并减少脱靶效应。
注：若用户实际指碳酸酐酶IV(Carbonic Anhydrase IV)，建议补充全称以便提供更精准的文献。
CA4 (Combretastatin A4) is a naturally occurring stilbenoid originally isolated from the African bush willow tree *Combretum caffrum*. It gained attention for its potent antitumor activity, primarily through disrupting microtubule dynamics and acting as a vascular-disrupting agent (VDA). By binding to tubulin, CA4 inhibits microtubule polymerization, leading to cytoskeletal collapse in endothelial cells lining tumor vasculature. This results in rapid occlusion of blood flow to tumors, causing ischemic necrosis while sparing normal tissue vasculature. Despite its efficacy in preclinical models, CA4's clinical application has been limited by poor water solubility, rapid metabolism, and dose-dependent toxicity.
To overcome these challenges, recombinant protein strategies have been explored. CA4 recombinant proteins often involve conjugation or fusion with carrier proteins (e.g., antibodies, albumin) or peptide tags to improve pharmacokinetics and tumor targeting. Some designs incorporate prodrug activation systems or nanotechnology-based delivery platforms to enhance specificity and reduce systemic exposure. Recombinant expression systems, such as *E. coli* or mammalian cells, enable scalable production of these engineered proteins. Recent advances include CA4-based antibody-drug conjugates (ADCs) and fusion proteins that synergize with immunotherapies by promoting tumor antigen exposure through vascular disruption. Ongoing research focuses on optimizing biodistribution, balancing efficacy with vascular toxicity, and addressing potential resistance mechanisms. These innovations aim to translate CA4's potent vascular-targeting properties into clinically viable cancer therapies with improved safety profiles.
×
